Prioritise CML Candidates Before Laboratory Testing
SilicoKinase Labs combines computational screening with laboratory validation to identify small molecules that may improve response to existing Chronic Myeloid Leukaemia (CML) treatments and help address treatment resistance.
01 · The challenge
Drug resistance in CML remains a major challenge.
Identifying compounds that may improve response to existing Chronic Myeloid Leukaemia treatments requires significant time, expertise, and laboratory resources. At the same time, there are vast numbers of potential molecules that could be explored.
Computational screening can help drug-discovery teams prioritise promising candidates before laboratory testing, allowing experimental resources to be focused on compounds with greater potential for further investigation.
02 · Our Approach
From possibilities to a focused shortlist.
Our computational approach helps identify and prioritise promising compounds with the potential to improve treatment response in CML
Screen
Explore large numbers of potential compounds using biological and chemical data
Prioritise
Prioritise promising compounds using computational analysis
Test
Advance selected candidates for expert review and laboratory validation
Ranked candidates
A ranked list of compounds recommended for further investigation and laboratory testing.
Clearer next steps
A clearer framework for deciding which compounds should progress to laboratory testing.
Supporting analysis
Computational analysis that helps explain how and why compounds have been prioritised.
Flexible delivery
A clearer framework for deciding which compounds should progress to laboratory testing.
03 · The Solution
Turn large numbers of potential compounds into a focused shortlist for investigation
SilicoKinase Labs is developing a computational screening approach to help pharmaceutical and biotechnology organisations identify and prioritise compounds for further investigation in CML.
Computational analysis is intended to complement, not replace, laboratory testing by helping organisations focus experimental work on promising candidates.
04 · WHO WE’RE SPEAKING TO
Built for teams making drug-development decisions.
Preclinical CROs
Teams delivering compound screening, preclinical testing and research services for pharmaceutical and biotechnology clients.
Pharmaceutical R&D
Drug-discovery and preclinical teams exploring targeted therapies and deciding which compounds should move forward.
Oncology Biotechnology
Biotechnology companies developing new cancer therapies and looking for more focused ways to identify promising candidates.
Computational Research
Researchers using biological insight, computational modelling and experimental evidence to guide what should be tested next.
Preclinical CROs
Teams delivering compound screening, preclinical testing and research services for pharmaceutical and biotechnology clients.
Pharmaceutical R&D
Drug-discovery and preclinical teams exploring targeted therapies and deciding which compounds should move forward.
Oncology Biotechnology
Biotechnology companies developing new cancer therapies and looking for more focused ways to identify promising candidates.
Computational Research
Researchers using biological insight, computational modelling and experimental evidence to guide what should be tested next.
05 · LOOKING TO THE FUTURE
Long-term Vision
Rather than focusing only on entirely new drugs, SilicoKinase Labs is exploring the potential of sensitising compounds that could be combined with established TKI therapies. By identifying compounds that may enhance the response to existing treatments, our longer-term vision is to develop combination strategies that could help address treatment resistance while building on therapies that are already established.
This could create opportunities to:
Improve the response to existing TKI therapies
Explore new approaches to treatment resistance
Potentially extend the therapeutic benefit of established treatments
Develop differentiated combination-treatment strategies
Create additional value around existing therapies
LET'S TALK
How does your organisation decide what to test next?
We're speaking with professionals working in pharmaceutical R&D, oncology biotechnology, and drug-discovery organisations to better understand how potential compounds are identified, prioritised, and progressed to laboratory testing.
If this is relevant to your work, we would welcome the opportunity to learn more about your experience, current challenges, and decision-making processes.